More than 6 million Americans are living with heart failure (HF) and the prevalence of this cardiovascular disease is projected to increase by 46% from 2012 to 2030. To meet this increasing need for care, the American Heart Association (AHA) is launching the Home Health Heart Failure Certification Program to evaluate home health use of AHA science and guidelines for HF patients.
Like the AHA, ChemImage is also exploring and developing ways to help heart failure patients and assist clinicians in assessment and monitoring by developing a non-invasive early indicator of acute HF decompensation called CardioVere. This cutting-edge technology objectively identifies levels of congestion in patients suffering from HF. CardioVere is the only handheld, non-invasive, non-contact device to monitor congestion in heart failure patients in all care settings, including home care.
As a leader in the field of hyperspectral imaging, ChemImage has recently published a clinical experience paper in the Journal of Biomedical Optics that describes the use of this technology in comparison to current non-objective congestion assessment techniques. This study validates CardioVere technology as an accurate heart failure assessment and monitoring device. The hyperspectral scientists and engineers at ChemImage are continuing to refine this technology for use across the HF patient care spectrum which includes home health. To find out more about CardioVere please visit https://cardiovere.com. To find out more information on heart failure please visit the AHA HF information page.
In the coming months, ChemImage will be posting blog updates on this groundbreaking technology. If you have any further questions on CardioVere or the ChemImage Life Science division please feel to contact Product Manager, Lew Lanker.
Virani, Salim S., et al. “Heart Disease and Stroke Statistics—2021 Update: A Report from the American Heart Association.” Circulation, vol. 143, no. 8, Feb. 2021.